BOEING CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BOEING CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.46B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $66.52B | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | $77.79B | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | $66.61B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $62.29B | Jan 31, 2024 |
| FY2020 | Dec 31, 2020 | $15.30B | Feb 1, 2021 |
| FY2020 | Sep 30, 2020 | $14.14B | Feb 1, 2021 |
| FY2020 | Jun 30, 2020 | $11.81B | Feb 1, 2021 |
| FY2020 | Mar 31, 2020 | $16.91B | Feb 1, 2021 |
| FY2020 | Dec 31, 2019 | $17.91B | Feb 1, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $76.56B | Jan 31, 2020 |
| FY2019 | Dec 31, 2018 | $101.13B | Jan 31, 2020 |
| FY2019 | Dec 31, 2017 | $94.01B | Jan 31, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.29B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.99B) | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | $7.72B | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | $3.53B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $3.05B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | ($5.69B) | Jan 27, 2023 |
| FY2021 | Dec 31, 2019 | $4.47B | Jan 31, 2022 |
| FY2020 | Dec 31, 2018 | $19.64B | Feb 1, 2021 |
| FY2019 | Dec 31, 2017 | $17.39B | Jan 31, 2020 |
| FY2018 | Dec 31, 2016 | $14.47B | Feb 8, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.24B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | ($11.82B) | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | ($2.22B) | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | ($4.94B) | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | ($4.20B) | Jan 31, 2024 |
| FY2020 | Dec 31, 2020 | ($8.42B) | Feb 1, 2021 |
| FY2020 | Sep 30, 2020 | ($449.00M) | Feb 1, 2021 |
| FY2020 | Jun 30, 2020 | ($2.38B) | Feb 1, 2021 |
| FY2020 | Mar 31, 2020 | ($628.00M) | Feb 1, 2021 |
| FY2020 | Dec 31, 2019 | ($1.01B) | Feb 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.28B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | ($10.71B) | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | ($773.00M) | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | ($3.52B) | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | ($2.87B) | Jan 31, 2024 |
| FY2020 | Dec 31, 2020 | ($8.05B) | Feb 1, 2021 |
| FY2020 | Sep 30, 2020 | ($401.00M) | Feb 1, 2021 |
| FY2020 | Jun 30, 2020 | ($2.96B) | Feb 1, 2021 |
| FY2020 | Mar 31, 2020 | ($1.35B) | Feb 1, 2021 |
| FY2020 | Dec 31, 2019 | ($2.20B) | Feb 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.62B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.81B | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | $3.38B | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | $2.85B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $2.25B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $2.48B | Jan 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.22B | Jan 31, 2022 |
| FY2020 | Dec 31, 2018 | $3.27B | Feb 1, 2021 |
| FY2019 | Dec 31, 2017 | $3.18B | Jan 31, 2020 |
| FY2018 | Dec 31, 2016 | $4.63B | Feb 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.07B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | ($12.08B) | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | $5.96B | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | $3.51B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | ($3.42B) | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | ($18.41B) | Jan 27, 2023 |
| FY2021 | Dec 31, 2019 | ($2.45B) | Jan 31, 2022 |
| FY2020 | Dec 31, 2018 | $15.32B | Feb 1, 2021 |
| FY2019 | Dec 31, 2017 | $13.35B | Jan 31, 2020 |
| FY2018 | Dec 31, 2016 | $10.50B | Feb 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.94B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.23B | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | $1.53B | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | $1.22B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $980.00M | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $1.30B | Jan 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.83B | Jan 31, 2022 |
| FY2020 | Dec 31, 2018 | $1.72B | Feb 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.74B | Jan 31, 2020 |
| FY2018 | Dec 31, 2016 | $2.61B | Feb 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.24B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $156.36B | Jan 30, 2026 |
| FY2024 | Dec 31, 2023 | $137.01B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $137.10B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | $138.55B | Jan 27, 2023 |
| FY2021 | Dec 31, 2020 | $152.14B | Jan 31, 2022 |
| FY2020 | Dec 31, 2019 | $133.63B | Feb 1, 2021 |
| FY2019 | Dec 31, 2018 | $117.36B | Jan 31, 2020 |
| FY2018 | Dec 31, 2017 | $112.36B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $90.00B | Feb 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $162.78B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $160.28B | Jan 30, 2026 |
| FY2024 | Dec 31, 2023 | $154.24B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $152.95B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | $153.40B | Jan 27, 2023 |
| FY2021 | Dec 31, 2020 | $170.21B | Jan 31, 2022 |
| FY2020 | Dec 31, 2019 | $141.93B | Feb 1, 2021 |
| FY2011 | Dec 31, 2011 | $76.38B | Feb 9, 2012 |
| FY2011 | Dec 31, 2010 | $65.70B | Feb 9, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.45B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | ($3.91B) | Jan 30, 2026 |
| FY2024 | Dec 31, 2023 | ($17.23B) | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | ($15.88B) | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | ($15.00B) | Jan 27, 2023 |
| FY2021 | Dec 31, 2020 | ($18.32B) | Jan 31, 2022 |
| FY2020 | Dec 31, 2019 | ($8.62B) | Feb 1, 2021 |
| FY2019 | Dec 31, 2018 | $339.00M | Jan 31, 2020 |
| FY2018 | Dec 31, 2017 | $1.66B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $817.00M | Feb 12, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.28B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $8.08B | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | $8.09B | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | $8.06B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $8.07B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $8.08B | Jan 27, 2023 |
| FY2021 | Dec 31, 2019 | $8.06B | Jan 31, 2022 |
| FY2020 | Dec 31, 2018 | $7.84B | Feb 1, 2021 |
| FY2019 | Dec 31, 2017 | $5.56B | Jan 31, 2020 |
| FY2018 | Dec 31, 2016 | $5.32B | Feb 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.25B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $15.36B | Jan 30, 2026 |
| FY2024 | Dec 31, 2023 | $27.25B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $29.47B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | $34.41B | Jan 27, 2023 |
| FY2021 | Dec 31, 2020 | $38.61B | Jan 31, 2022 |
| FY2020 | Dec 31, 2019 | $50.64B | Feb 1, 2021 |
| FY2019 | Dec 31, 2018 | $55.94B | Jan 31, 2020 |
| FY2018 | Dec 31, 2017 | $49.62B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $40.71B | Feb 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.92B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $13.80B | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | $12.69B | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | $14.61B | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | $8.05B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $7.75B | Jan 27, 2023 |
| FY2021 | Dec 31, 2019 | $9.49B | Jan 31, 2022 |
| FY2020 | Dec 31, 2018 | $7.64B | Feb 1, 2021 |
| FY2019 | Dec 31, 2017 | $8.81B | Jan 31, 2020 |
| FY2018 | Dec 31, 2016 | $8.80B | Feb 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.85B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | $53.63B | Jan 30, 2026 |
| FY2024 | Dec 31, 2023 | $52.06B | Feb 3, 2025 |
| FY2023 | Dec 31, 2022 | $56.79B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | $57.92B | Jan 27, 2023 |
| FY2021 | Dec 31, 2020 | $63.38B | Jan 31, 2022 |
| FY2020 | Dec 31, 2019 | $20.96B | Feb 1, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | (18) | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | (8) | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | (7) | Jan 31, 2024 |
| FY2020 | Dec 31, 2020 | (14) | Feb 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 1, 2021 |
| FY2020 | Jun 30, 2020 | (4) | Feb 1, 2021 |
| FY2020 | Mar 31, 2020 | (1) | Feb 1, 2021 |
| FY2020 | Dec 31, 2019 | (1) | Feb 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | (18) | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Jan 30, 2026 |
| FY2024 | Dec 31, 2022 | (8) | Feb 3, 2025 |
| FY2023 | Dec 31, 2021 | (7) | Jan 31, 2024 |
| FY2020 | Dec 31, 2020 | (14) | Feb 1, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 1, 2021 |
| FY2020 | Jun 30, 2020 | (4) | Feb 1, 2021 |
| FY2020 | Mar 31, 2020 | (1) | Feb 1, 2021 |
| FY2020 | Dec 31, 2019 | (1) | Feb 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.01B | Jan 30, 2026 |
| FY2025 | Dec 31, 2024 | 1.01B | Jan 30, 2026 |
| FY2025 | Dec 31, 2023 | 1.01B | Jan 30, 2026 |
| FY2025 | Dec 31, 2022 | 1.01B | Jan 30, 2026 |
| FY2024 | Dec 31, 2021 | 1.01B | Feb 3, 2025 |
| FY2023 | Dec 31, 2020 | 1.01B | Jan 31, 2024 |
| FY2022 | Dec 31, 2019 | 1.01B | Jan 27, 2023 |
| FY2021 | Dec 31, 2018 | 1.01B | Jan 31, 2022 |
| FY2020 | Dec 31, 2017 | 1.01B | Feb 1, 2021 |
| FY2019 | Dec 31, 2016 | 1.01B | Jan 31, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2020 | $1.16B | Jan 27, 2023 |
| FY2021 | Dec 31, 2019 | $4.63B | Jan 31, 2022 |
| FY2020 | Dec 31, 2018 | $3.95B | Feb 1, 2021 |
| FY2019 | Dec 31, 2017 | $3.42B | Jan 31, 2020 |
| FY2018 | Dec 31, 2016 | $2.76B | Feb 8, 2019 |
| FY2017 | Dec 31, 2015 | $2.49B | Feb 12, 2018 |
| FY2016 | Dec 31, 2014 | $2.12B | Feb 8, 2017 |
| FY2015 | Dec 31, 2013 | $1.47B | Feb 10, 2016 |
| FY2014 | Dec 31, 2012 | $1.32B | Feb 12, 2015 |
| FY2013 | Dec 31, 2011 | $1.24B | Feb 14, 2014 |